Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review

References

• Aitken M, Valkova S. Avoidable costs in U.S. healthcare: the $200 billion opportunity from using medicines more responsibly. IMS Institute for Healthcare Informatics, 2013. Availabe from: http://www.imshealth.com/files/web/IMSH%20Institute/Reports/Avoidable_Costs_in%20_US_Healthcare/IHII_AvoidableCosts_2013.pdf. [cited 2016 May 10]
   Google Scholar
• Gyllensten H, Hakkarainen KM, Jonsson AK, et al. Modelling drug-related morbidity in Sweden using an expert panel of pharmacists’. Int J Clin Pharm. 2012;34:538–546.
   PubMed Web of Science ®Google Scholar
• Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42:1017–1025.
   PubMed Web of Science ®Google Scholar
• Baena MI, Fajardo PC, Pintor-Marmol A, et al. Negative clinical outcomes of medication resulting in emergency department visits. Eur J Clin Pharmacol. 2014;70:79–87.
   PubMed Web of Science ®Google Scholar
• Cipolle J, Strand LM, Morley PC. A reimbursement system for pharmaceutical care: pharmaceutical care practice. New York: McGraw-Hill; 1998.
   Google Scholar
• Saez-Benito L, Fernandez-Llimos F, Feletto E, et al. Evidence of the clinical effectiveness of cognitive pharmaceutical services for aged patients. Age Ageing. 2013;42:442–449.
   PubMed Web of Science ®Google Scholar
• Malet-Larrea A, Goyenechea E, Garcia-Cardenas V, et al. The impact of a medication review with follow-up service on hospital admissions in aged polypharmacy patients. Br J Clin Pharmacol. 2016;82:831–838.
   PubMed Web of Science ®Google Scholar
• Pande S, Hiller JE, Nkansah N, et al. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013;2:CD010398.
   Google Scholar
• Perez A, Doloresco F, Hoffman JM, et al. ACCP: economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 2009;29:128.
   PubMedGoogle Scholar
• Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23:113–132.
   PubMed Web of Science ®Google Scholar
• Schumock GT, Meek PD, Ploetz PA, et al. Economic evaluations of clinical pharmacy services–1988-1995. Pharmacotherapy. 1996;16:1188–1208.
   PubMed Web of Science ®Google Scholar
• Touchette DR, Doloresco F, Suda KJ, et al. Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34:771–793.
   PubMed Web of Science ®Google Scholar
• Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36:1101–1114.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Libr. 2011 updated Mar; cited 2015 Sept 8; Available from www.cochrane-handbook.org
   Google Scholar
• NHS Centre for Reviews and Dissemination. NHS economic evaluation database handbook. UK: University of York; 2007; Available from http://www.york.ac.uk/inst//crd/pdf/nhseed-handbook2007.pdf
   Google Scholar
• Liberati AA, Tetzlaff DGMulrow J, et al. Prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj-brit Med J. 2009;339:b2700.
   Google Scholar
• Moher DL, Tetzlaff A, Altman J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford (UK): Oxford University Press; 2005.
   Google Scholar
• Benrimoj SI, Feletto E, Gastelurrutia MA, et al. A holistic and integrated approach to implementing cognitive pharmaceutical services. Ars Pharm. 2010;51:69–87.
   Google Scholar
• The InterTASC Information Specialists’ Sub-Group Search Filter Resource (UK). Filters to find economic evaluations [internet]. Available from: https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/filters-to-find-i [ cited 2015 sept 20].
   Google Scholar
• EPOC Guidance on Risk of Bias. EPOC. Suggested risk of bias criteria for EPOC reviews. Available from: http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf [ cited 2016 May 11].
   Google Scholar
• Evers S, Goossens M, De Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240–245.
   PubMed Web of Science ®Google Scholar
• Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess (Rockv). 2004;8:172.
   Web of Science ®Google Scholar
• Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence & Policy. 2010;6:51–59.
   Web of Science ®Google Scholar
• Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19:350–364.
   PubMed Web of Science ®Google Scholar
• Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. Bmj. 2001;322:1596–1598.
   PubMed Web of Science ®Google Scholar
• Martínez-Martínez F, Gastelurrutia MA, Benrimoj SI, et al. [conSIGUE: clinical, economic and humanistic impact of the medication review with follow-up service in aged polypharmacy patients in Spanish community pharmacy]. Madrid. Madrid: Spanish General Council of Official Colleges of Pharmacists; 2014. ISBN: 978-84-87276-83-5.
   Google Scholar
• Bernsten C, Bjorkman I, Caramona M, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging. 2001;18:63–77.
   PubMed Web of Science ®Google Scholar
• Bond CM, Fish A, Porteous TH, et al. A randomised controlled trial of the effects of note-based medication review by community pharmacists on prescribing of cardiovascular drugs in general practice. Ijpp. 2007;15:39–46.
   Google Scholar
• Bosmans JE, Brook OH, Van Hout HP, et al. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. PharmacoEconomics. 2007;25:25–37.
   PubMed Web of Science ®Google Scholar
• Bond C. Community Pharmacy Medicines Management Project Evaluation T. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract. 2007;24:189–200.
   PubMed Web of Science ®Google Scholar
• Elliott RA, Barber N, Clifford S, et al. The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Pharm World Sci. 2008;30:17–23.
   PubMedGoogle Scholar
• Gordois A, Armour C, Brillant M, et al. Cost-effectiveness analysis of a pharmacy asthma care program in Australia. Dis Manag Health Outcomes. 2007;15:387–396.
   Web of Science ®Google Scholar
• Jodar-Sanchez F, Malet-Larrea A, Martin JJ, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33:599–610.
   PubMed Web of Science ®Google Scholar
• Krass I, Armour C, Taylor S, et al. Pharmacy diabetes care program. Final Report. Australia. 2005. [cited 2015 Oct 20]. Available from: http://guild.org.au/services-programs/research-and-development/archive---third-agreement/2002-518.
   Google Scholar
• McLean W, Gillis J, Waller R. The BC community pharmacy asthma study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J. 2003;10:195–202.
   PubMedGoogle Scholar
• Rubio-Valera M, Bosmans J, Fernandez A, et al. Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR study). Plos One. 2013;8:e70588.
   PubMed Web of Science ®Google Scholar
• Scott A, Tinelli M, Bond C. Community pharmacy medicines management evaluation T. Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives. Pharmacoeconomics. 2007;25:397–411.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Johnson JA, Tsuyuki RT. Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy. 2001;21:627–635.
   PubMed Web of Science ®Google Scholar
• Sturgess IK, McElnay JC, Hughes CM, et al. Community pharmacy based provision of pharmaceutical care to older patients. Pharm World Sci. 2003;25:218–226.
   PubMedGoogle Scholar
• Bojke C, Philips Z, Sculpher M, et al., Respect Trial Team. Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. Br J Gen Pract. 2010;60:e20- e7.
   PubMedGoogle Scholar
• Van Boven JF, Tommelein E, Boussery K, et al. Optimalisation de la pharmacothérapie en pharmacie d’officine chez des patients atteints de Bronchopneumopathie Chronique Obstructive (BPCO): une analyse coût-efficacité. J Pharm Belg. 2014;96:15–16.
   Google Scholar
• Van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res. 2014;15:66.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
   Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178.
   PubMedGoogle Scholar
• Elliott RA, Putman K, Davies J, et al. A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions. PharmacoEconomics. 2014;32:1185–1199.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value in Health. 2013;16:231–250.
   PubMed Web of Science ®Google Scholar
• Drummond MF. Comparing cost-effectiveness across countries: the model of acid-related disease. Pharmacoeconomics. 1994;5:60–67.
   Google Scholar
• Thomson S, Foubister T, Figueras J, et al. Addressing financial sustainability in health systems. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2009. [cited 2016 Jul 27]. Available from http://www.euro.who.int/__data/assets/pdf_file/0005/64949/E93058.pdf?ua=1
   Google Scholar